TNF and inflammatory bowel disease: Approximately 30% of IBD patients do not initially respond to anti-TNF therapy (primary non-responders), and of those who do benefit, 40% to 50% experience a decline in efficacy within the first year, necessitating dose adjustments or a change in treatment, a phenomenon known as “secondary loss of response or immunogenicity” [1].